Last reviewed · How we verify
Non-influenza Comparator Vaccine
A non-influenza comparator vaccine stimulates the immune system to generate protective antibodies and cellular immunity against a non-influenza pathogen or antigen.
A non-influenza comparator vaccine stimulates the immune system to generate protective antibodies and cellular immunity against a non-influenza pathogen or antigen. Used for Phase 3 comparator vaccine (specific indication unknown without trial protocol details).
At a glance
| Generic name | Non-influenza Comparator Vaccine |
|---|---|
| Sponsor | Seqirus |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Comparator vaccines in clinical trials are used as control arms to evaluate the efficacy and safety of investigational vaccines. This non-influenza comparator vaccine likely contains inactivated viral antigens, recombinant proteins, or other immunogenic components designed to elicit both humoral and cell-mediated immune responses. The specific mechanism depends on the vaccine platform and target antigen, but generally works by presenting foreign antigens to the immune system to generate memory B and T cells.
Approved indications
- Phase 3 comparator vaccine (specific indication unknown without trial protocol details)
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Systemic reactions (fever, fatigue, myalgia)
- Headache
Key clinical trials
- Efficacy Study With QIVc in Pediatric Subjects (PHASE3)
- Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age (PHASE2)
- A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women. (PHASE3)
- A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age (PHASE3)
- Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older (PHASE1, PHASE2)
- Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children. (PHASE3)
- Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Elderly (PHASE3)
- Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Non-influenza Comparator Vaccine CI brief — competitive landscape report
- Non-influenza Comparator Vaccine updates RSS · CI watch RSS
- Seqirus portfolio CI